Synopsys reports after the bell on August 26 with a notable divergence: short sellers are stepping back even as the stock sits roughly 30% below where analysts think it should trade.
The lending market tells a clear story of fading conviction from the short side. Short interest has fallen to 2.8% of the float — modest at the best of times — and declined a further 1.4% over the past week. Borrowing costs have dropped sharply, down 35% week-on-week to just 0.32%. Borrow availability is effectively unlimited, with shares to lend far exceeding current demand. The ORTEX short score of 33 reflects all of this: bears are not pressing the trade into the print. Options positioning has also eased. The put/call ratio came in at 1.17, fractionally below its 20-day average of 1.20, a mild read that suggests no unusual rush to hedge downside. The stock shed 4.5% over the past week to close at $394.51, continuing to lag after May's brutal 10% single-day drop on the prior quarter's results.
The central tension heading into this print is valuation versus momentum. The consensus mean target is $560 — roughly 42% above Monday's close — making the implied upside unusually wide for a mega-cap software name. Morgan Stanley lowered its target to $500 from $525 as recently as August 19, while Wells Fargo cut to $450 from $535 a week before that. Both houses remain neutral-rated. Against that, Benchmark initiated at Buy with a $570 target in July, and Piper Sandler upgraded to Overweight in late June with a $550 target. Bulls point to Synopsys's dominance in electronic design automation, accelerating forward earnings expectations, and the AI-driven surge in chip design complexity that plays directly to its toolset. Bears counter with geographic fragmentation risk as governments fund domestic chip design ecosystems, and the potential for large systems companies to develop more design capability in-house over time.
Institutional holders have been broadly adding. UBS Asset Management added over 1.3 million shares in the most recent reported period, and T. Rowe Price added 567,000. Insider activity has been confined to routine award-and-sell patterns, with no material open-market buying. The last earnings print ended with a 10% single-day decline and a further 6.8% loss over the five days that followed — a reaction still weighing on the stock's one-year performance.
Tomorrow's print will test whether SNPS can deliver enough guidance clarity to close even a fraction of the gap between where it trades and where analysts believe it is worth — and whether the EDA growth story holds at a moment when the competitive backdrop is becoming meaningfully more complicated.
See the live data behind this article on ORTEX.
Open SNPS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
